- 期刊
Circulating Total and ActiveMetalloproteinase-9 and Tissue Inhibitor ofMetalloproteinases-1 in Patients with Systemic Lupus Erythomatosus
延伸閱讀
- Shahin, A., Elsawaf, A., Ramadan, S., Shaker, O., Amin, M., & Taha, M. (2006). Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in Patients With Systemic Sclerosis With Duration More Than 2 Years: Correlation With Cardiac and Pulmonary Abnormalities. Mediators of Inflammation, 2006(), 205-210. https://doi.org/10.1155/MI/2006/38458
- Chen, S. J. (2012). Pharmacological modulation and its mechanism on the expression of the inhibitory Fc receptor in B cells as atherapeutic for systemic lupus erythematosus [master's thesis, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU.2012.03380
- Sun, J. (2010). Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases Are Essential for the Inflammatory Response in Cancer Cells. Journal of Signal Transduction, 2010(), 55-61. https://doi.org/10.1155/2010/985132
- Shen, G., & Ma, X. (2016). High Levels of 17β-Estradiol Are Associated with Increased Matrix Metalloproteinase-2 and Metalloproteinase-9 Activity in Tears of Postmenopausal Women with Dry Eye. Journal of Ophthalmology, 2016(), 372-379-050. https://doi.org/10.1155/2016/2415867
- Bartkowiak, B. D., Waszczykowska, E., Zalewska, A., & Jedrzejowska, A. S. (2005). Correlation of Endostatin and Tissue Inhibitor of Metalloproteinases 2 (TIMP2) Serum Levels With Cardiovascular Involvement in Systemic Sclerosis Patients. Mediators of Inflammation, 2005(), 144-149. https://doi.org/10.1155/MI.2005.144